IPO

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Parabilis prices IPO at an ambitious $475 million

Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.

News

Heart drug developer Kardigan files IPO

The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.

News

Tuneable peptide biotech Parabilis files IPO

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.

News

Autoimmune disease biotech Odyssey sets terms for $225m IPO

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

News

Avalyn seeks $300m from its IPO

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis prices IPO at an ambitious $475 million

Heart drug developer Kardigan files IPO

Tuneable peptide biotech Parabilis files IPO

Autoimmune disease biotech Odyssey sets terms for $225m IPO

Avalyn seeks $300m from its IPO

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

IPO

Editor's Picks